Filing Details
- Accession Number:
- 0001609351-16-000095
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2016-08-17 16:31:53
- Reporting Period:
- 2016-08-15
- Filing Date:
- 2016-08-17
- Accepted Time:
- 2016-08-17 16:31:53
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1609351 | Spark Therapeutics Inc. | ONCE | Biological Products, (No Disgnostic Substances) (2836) | 462654405 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1631248 | A Katherine High | C/O Spark Therapeutics, Inc. 3737 Market Street, Suite 1300 Philadelphia PA 19104 | See Remarks | Yes | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2016-08-15 | 5,000 | $61.88 | 235,000 | No | 4 | S | Direct | |
Common Stock | Disposition | 2016-08-15 | 1,458 | $62.79 | 233,542 | No | 4 | S | Direct | |
Common Stock | Disposition | 2016-08-15 | 3,342 | $63.94 | 230,200 | No | 4 | S | Direct | |
Common Stock | Disposition | 2016-08-15 | 200 | $64.59 | 230,000 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Footnotes
- The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 3, 2016.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.52 to $62.51, inclusive. The reporting person undertakes to provide to Spark Therapeutics, Inc., any security holder of Spark Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.53 to $63.50, inclusive. The reporting person undertakes to provide to Spark Therapeutics, Inc., any security holder of Spark Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.58 to $64.56, inclusive. The reporting person undertakes to provide to Spark Therapeutics, Inc., any security holder of Spark Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4.